Adaptive responses as mechanisms of resistance to braf inhibitors in melanoma
The introduction of v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors in melanoma patients with BRAF (V600E) mutations has demonstrated significant clinical benefits. However, rarely do tumours regress completely. Frequently, the reason for this is that therapies targeting specific onc...
| Main Authors: | , |
|---|---|
| Format: | Journal Article |
| Language: | English |
| Published: |
MDPI
2019
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.11937/77890 |